GLP-1 Benefits Beyond the Scale

The cardiovascular finding that changed the conversation

In 2023, the SELECT trial published results from 17,604 adults who had existing cardiovascular disease and excess weight but *not* diabetes. Over roughly three years, those taking semaglutide had 20% fewer major cardiovascular events — heart attack, stroke, and cardiovascular death — than those on placebo.

That last point is the interesting one. The curves separated sooner than the weight difference could explain, which suggests GLP-1 medication is doing something directly to vascular inflammation, not merely removing weight from the equation. It is the reason semaglutide has an FDA indication for cardiovascular risk reduction, and one of the arguments in its favour when patients weigh it against tirzepatide in Semaglutide vs. Tirzepatide: Which Is Right for You?.

Blood pressure and cholesterol

Across the weight-management trials, systolic blood pressure fell by roughly 5–7 mmHg on average. That is not a rounding error — a sustained 5 mmHg reduction across a population is associated with a meaningful drop in stroke risk. Triglycerides typically fall substantially, and markers of inflammation like C-reactive protein drop alongside them.

⭐⭐⭐⭐⭐

“My doctor took me off one of my blood pressure pills at the six-month mark. I have been on that prescription since 2011. I did not expect that to be part of this.”

Blood sugar and type 2 diabetes

This is where the whole class began. GLP-1 medication improves glucose control by prompting insulin release only when blood sugar is actually rising, suppressing glucagon, and slowing how quickly carbohydrate arrives from the stomach. In people with prediabetes, GLP-1 treatment substantially reduces progression to type 2 diabetes; in people who already have it, HbA1c reductions of 1.5–2.0 percentage points are common.

Because the insulin effect is glucose-dependent, GLP-1 medication does not cause low blood sugar on its own. It can, however, amplify the effect of insulin or sulfonylureas — another reason your full medication list belongs in your consultation.

Liver health

Metabolic dysfunction-associated steatotic liver disease — the condition previously called fatty liver — affects a large share of adults with excess weight and usually produces no symptoms at all until it is advanced. GLP-1 treatment reduces liver fat content substantially, and trials have shown resolution of the inflammatory form, MASH, in a significant proportion of participants without worsening of fibrosis.

Many patients discover their liver enzymes were mildly elevated only when they normalise. It is one of the quieter wins in the The GLP-1 Results Timeline, Month by Month.

Sleep apnoea and sleep quality

Excess weight around the neck and abdomen narrows the airway and restricts the diaphragm. Reducing it improves both. In the SURMOUNT-OSA trials, tirzepatide produced large reductions in apnoea-hypopnoea events, and a substantial share of participants improved enough to change their treatment requirements.

Patients rarely put it in clinical terms. They say they stopped waking at 3am, or that their partner stopped moving to the spare room.

Joints and mobility

Every pound lost takes roughly four pounds of load off each knee with every step. Twenty pounds down is eighty pounds less force through a joint thousands of times a day. Patients consistently report knee and hip pain improving in months two through four — often before they consider the weight loss itself significant.

This creates a virtuous circle worth planning for: less joint pain makes movement possible, and movement is what protects lean mass during weight loss. That is the whole argument of Protecting Muscle While You Lose Fat.

The ones patients mention first

Research still underway

Several areas are promising but not settled, and we would rather say so plainly than overstate them: chronic kidney disease progression, addictive behaviours including alcohol use, knee osteoarthritis pain, and possible neuroprotective effects. Some have encouraging early trial data. None are established indications, and none should be a reason to start treatment on their own.